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Abstract 
Background: Most previous studies used aluminum hydroxide‑absorbed allergen extracts in evaluating the poten‑
tial therapeutic roles of intralymphatic allergen‑specific immunotherapy (ILAIT). In this study, we evaluated the thera‑
peutic efficacy and safety of ILAIT with L‑tyrosine‑adsorbed allergen extracts of Dermatophagoides farinae, D. pteronys-
sinus, cat, dog, or mixtures thereof, in patients with allergic rhinitis induced by these allergens.
Methods: In this randomized, double‑blind, placebo‑controlled trial, study subjects received three intralymphatic 
injections of L‑tyrosine‑adsorbed allergen extracts (active group) or saline (placebo group) at 4‑week intervals.
Results: Although ILAIT reduced daily medication use and skin reactivity to HDM and cat allergens at 4 months after 
treatment, overall symptom score on a visual analog scale (VAS), sinonasal outcome test‑20 (SNOT‑20), rhinoconjunc‑
tivitis quality of life questionnaire (RQLQ), daily symptom score (dSS), daily medication score (dMS), daily symptom 
medication score (dSMS), nasal reactivity to HDM allergen, and basophil activity to HDM, cat, and dog allergens at 
4 months and 1 year after treatment were similar between the treatment and control groups. Intralymphatic injection 
was more painful than a venous puncture, and pain at the injection site was the most frequent local adverse event 
(12.8%); dyspnea and wheezing were the most common systemic adverse events (5.3%).
Conclusions: ILAIT with L‑tyrosine‑adsorbed allergen extracts does not exhibit profound therapeutic efficacy in aller‑
gic rhinitis and can provoke moderate‑to‑severe systemic reactions and cause pain at the injection site.
Trial registration: clinicaltrials.gov: NCT02665754; date of registration: 28 January 2016
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Background
Intralymphatic allergen-specific immunotherapy 
(ILAIT) was developed over a decade ago to overcome 
the shortcomings of conventional allergen-specific 
immunotherapy (AIT), such as systemic hypersen-
sitivity reactions and the need for prolonged treat-
ment [1]. The therapeutic effects of ILAIT have been 
demonstrated in numerous studies. Notably, three 
intralymphatic injections of allergen can alleviate pol-
len-induced allergic rhinitis (AR) [1–10], although one 
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study reported no therapeutic effect after three or six 
intralymphatic injections of grass pollen allergen [11]. 
A few studies have assessed the efficacy and safety of 
ILAIT in patients with AR induced by inhalant aller-
gens from cats, dogs, and house dust mites (HDM), 
such as Dermatophagoides farinae and D. pteronyssinus 
[12–16]. In ILAIT, aluminum hydroxide-absorbed aller-
gen extracts were used in most studies [1–8, 10–13, 
16], while aqueous allergen extracts were used in only 
one clinical trial [14, 15].
ILAIT has been shown to provoke mild local and 
systemic adverse reactions [1–4, 6, 8, 9, 11, 12, 16], 
although a few studies reported moderate-to-severe 
hypersensitivity reactions requiring intramuscular epi-
nephrine injection or bronchodilator inhalation [5, 7, 
14]. Thus, the clinical usefulness and safety of ILAIT 
using different allergen preparations remain unclear.
In this study, we evaluated the treatment outcomes 
and adverse effects of ILAIT using L-tyrosine-adsorbed 
allergen extracts of D. farinae, D. pteronyssinus, dog, 
cat, or mixtures thereof in patients with AR induced by 
one or more of these allergens.
Methods
Study subjects
The study was conducted at the outpatient clinics of five 
university hospitals in the Republic of Korea. From July 
2016 to December 2018, the study included individu-
als with AR induced by individual or combined aller-
gens from D. farinae, D. pteronyssinus, dogs, and cats. 
Patient selection was based on the following inclusion 
criteria [14, 15]. (1) Sensitization confirmed by a skin 
prick test (SPT) or allergen-specific immunoglobulin E 
(IgE) serum levels. Subjects with an allergen-to-hista-
mine ratio of ≥ 1 or an allergen-specific IgE serum level 
of ≥ 0.35 kU/L were regarded as sensitized to an aller-
gen. (2) Complaints of AR symptoms upon exposure to 
house dust, dogs, or cats. Patients with mild asthma and 
those sensitized to pollen allergens were included in the 
study if there was no definite allergic symptom dur-
ing the pollen season. Patients with severe or uncon-
trolled asthma (forced expiratory volume in 1  s ≤ 50%, 
predicted); tyrosinemia; alkaptonuria; severe underly-
ing conditions, including hepatic, renal, hematologic, 
oncologic, immunologic, infectious, or cardiovascular 
diseases; acute (within 1 month) or chronic respiratory 
diseases other than asthma, such as the common cold, 
flu, bronchiectasis, or chronic obstructive pulmonary 
disease; or previous AIT, were excluded. Pregnant or 
lactating women were also excluded. Written informed 
consent was obtained from all subjects included in the 
study.
Randomization and blinding
Radiologists who performed intralymphatic injec-
tions randomly assigned subjects (1:1) into treatment 
and control groups using Microsoft Excel (Microsoft, 
Redmond, WA, USA) with a block size of 10. Other 
researchers prescribing medication and assessing treat-
ment outcomes and adverse events were blinded to the 
treatment; blinding was maintained until all assess-
ments and recordings were completed.
Intervention
Subjects in the active group were administered three 
injections (0.1  mL) of the respective allergen extract 
at 4-week intervals. Using ultrasound guidance and a 
25-gauge needle, L-tyrosine-adsorbed allergen extracts 
(Tyrosine S®; Allergy Therapeutics, Worthing, UK) 
were aseptically injected into the superficial inguinal 
lymph node in the right side of the groin. Before the 
injections, aspiration was performed to avoid inad-
vertent intravascular administration. After each injec-
tion, subjects were closely monitored for 1 h, and vital 
signs were assessed at 5-min intervals; any adverse 
events were recorded. Adverse events due to previous 
injections were also evaluated before the next injec-
tion. Allergens were initially administered at a 1000-
fold dilution of the highest dose used for subcutaneous 
immunotherapy (SCIT) [14]. For the second and third 
injection, the administered dose was 3 and 10 times the 
initial allergen concentration, respectively [6, 12, 14]. 
Subjects in the control group received three injections 
(0.1 mL) of normal saline at 4-week intervals.
Outcome measures
Patients were asked to answer the questionnaires and 
complete diary that measured allergic symptoms and 
rescue medication, as well as underwent a SPT and 
intradermal test (IDT) before treatment, at 4  months 
after treatment, and at 1  year after treatment (Fig.  1) 
[14]. For subjects who were enrolled at the central insti-
tution and whose target allergens were HDMs, a nasal 
allergen provocation test (NAPT) was also performed 
[14].
Overall treatment effects
Subjects were asked to score their overall AR symptoms 
on a visual analog scale (VAS) ranging from 0 (none) to 
100 (extremely severe).
QOL
Quality of life (QOL) was evaluated using the Korean 
version of the sinonasal outcome test-20 (SNOT-20) 
and rhinoconjunctivitis QOL questionnaire (RQLQ) 
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[14, 17, 18]. The RQLQ score was used as the primary 
outcome measure.
Symptom medication score
Subjects self-reported a daily symptom score (dSS) for 
runny nose, blocked nose, sneezing, and itchy nose the 
month before treatment, as well as at 4 months and 1 year 
after treatment. For the dSS, a four-point scale was used: 
0, no symptoms; (1) mild symptoms (easily tolerated); 
(2) moderate symptoms (bothersome but tolerable); (3) 
severe symptoms (hard to tolerate and interfering with 
daily activities) [19]. The patients were provided antihis-
tamines or nasal glucocorticosteroid spray in a stepwise 
fashion according to Allergic Rhinitis and its Impact on 
Asthma (ARIA) recommendations [14, 19–21]. Rhinitis 
medication use was scored to obtain the daily medication 
score (dMS), and the daily symptom medication score 
(dSMS) was calculated as the sum of the dSS and dMS 
[19].
SPT and IDT
The SPT and IDT were performed using serially diluted 
extracts of the respective allergen (D. farinae, D. ptero-
nyssinus, dog, or cat; Tyrosine S®; Allergy Therapeu-
tics). The skin test results were interpreted after 15 min 
by measuring the mean wheal diameter induced by each 
allergen, using calipers with resolution of 0.01 mm.
NAPT
Subjects sensitized to HDMs underwent NAPT at the 
central institution with saline and freshly reconstituted 
freeze-dried allergen solutions of Der f 1 (0.04, 0.4, 1, 
2, and 4  μg/mL) at 15-min intervals [14, 22]. At each 
step, two puffs (0.05  mL each) of the solution at room 
temperature were applied to each nasal passage using a 
metered pump spray; nasal obstruction, rhinorrhea, itch-
ing, sneezing, and ocular symptoms were recorded by 
placing a vertical mark on a horizontal 100  mm line or 
using a VAS, with the total VAS score calculated as the 
sum of five VAS scores (total range, 0–500) [14, 22, 23]. 
Measurements were taken before the NAPT (baseline 
VAS) and at 15  min after each challenge [14]. Acoustic 
rhinometry was performed using an SRE 2000 rhinom-
eter (Rhinometrics, Lynge, Denmark) according to the 
guidelines of the Standardization Committee on Acoustic 
Rhinometry [24]. The mean volume  (cm3) in the anterior 
nasal segment (2–6-cm volume) was measured before 
the NAPT (baseline test) and at 15 min after each chal-
lenge [14, 22]. Following the protocol in a previous report 
[4], the total VAS score and the 2–6 cm volume at differ-
ent time points (15 min intervals) were plotted. The area 
under the curve (AUC) values for those two variables 
were calculated for every patient.
Basophil activation test
Blood was drawn (at the central institution) from 15 
subjects (eight in the active group and seven in the con-
trol group) for a basophil activation test (BAT) before 
treatment, as well as at 4 months and 1 year after treat-
ment. The cells were stimulated with the respective aller-
gen within 2  h of blood sampling using a commercially 
available Flow-CAST kit (Bühlmann Laboratories AG, 
Schönenbuch, Switzerland) according to the manufactur-
er’s and previously described instructions [25].
Statistical analyses
Statistical analyses were performed using PASW 20.0 
(SPSS Inc. Chicago, IL, USA) and GraphPad Prism 6.01 
software (GraphPad Software, La Jolla, CA, USA). Con-
tinuous variables were analyzed with the Man-Whitney 
U test for intergroup analysis, and the Wilcoxon signed-
rank test for intragroup analysis. Categorical variables 
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Fig. 1 Study outline. At visit 1, rescue medications were prescribed, and diary cards were issued after informed consents were obtained; at visit 
2, pre‑ILAIT status was evaluated; at visits 3 to 5, subjects received intralymphatic immunotherapeutic allergen injection; at visits 6 to 7, post‑ILAIT 
status was evaluated, respectively. ILAIT intralymphatic allergen‑specific immunotherapy, HDM house dust mite
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P-values < 0.05 were considered to indicate statistical 
significance.
Minimum sample size calculation
A power calculation was performed with a two-sam-
ple t-test for the primary outcome (mean total score of 
RQLQ). We expected a clinically significant score differ-
ence of 0.50 in mean total score of RQLQ between the 
two groups at 4 months after treatment [26]. Assuming a 
standard deviation of 0.61 based on a previous pilot study 
[14], and aiming for a power of 0.80, type-1 error rate of 
0.05, and loss to follow-up rate of 40%, the required total 
sample size was calculated to be 38.
Ethics
The study was conducted in accordance with good clini-
cal practice guidelines [27]. The study was approved by 
the Ministry of Food and Drug Safety of the Republic 
of Korea (20,160,004,728) and our institutional review 
boards (GBIRB2016-002, 3-2017-0307, 26-2017-45, 
B1707-409-401, and AJIRB-MED-CT1-17-098). The 
study was monitored by our human research protection 
committees and registered in an open-access trial regis-
try (ClinicalTrials.gov identifier: NCT02665754).
Results
Study subjects
A schematic representation of patient selection is shown 
in Fig.  2. Thirty-eight subjects were initially enrolled 
in the study; among them, five subjects rejected to be 
enrolled, and one developed an anaphylactic reaction 
during the IDT with a target allergen. Thirty-two sub-
jects were randomly allocated into treatment (n = 19) 
and control (n = 13) groups, and each subject received 
three intralymphatic injections of target allergens or a 
placebo; one patient in the active group withdrew from 
the study after receiving only one injection but was still 
considered for the ILAIT safety evaluation. Another sub-
ject in the active group withdrew from the study after 
receiving three intralymphatic injections due to a lack 
of time. The therapeutic efficacy of ILAIT was evaluated 
(in 17 subjects in the active group and 13 in the control 
group) at 4  months after the first intralymphatic injec-
tion. Subsequently, the therapeutic efficacy of ILAIT was 
re-accessed at 1 year after the first intralymphatic injec-
tion; as eight subjects (four in the active group and four 
in the placebo group) withdrew due to lack of time, the 
1-year follow-up was conducted for 22 subjects (13 in the 
active group and nine in the control group).
The baseline characteristics of the study sub-
jects are summarized in Table  1. The mean age was 
Assessed for eligibility (n=38)
Reject (n=5)
Anaphylaxis during IDT (n=1)
Randomization (n=32)
Active group (n=19) Control group (n=13)
Safety population (n=19) Safety population (n=13)
Drop out due to lack of time 
(n=2)
Efficacy population
4 months after ILAIT
(n=17)
Efficacy population
4 months after ILAIT
(n=13)
Drop out due to lack of time 
(n=4)
Efficacy population
1 year after ILAIT
(n=13)
Drop out due to lack of time 
(n=4)
Efficacy population
1 year after ILAIT
(n=9)
Fig. 2 Participant flowchart. IDT intradermal test, ILAIT intralymphatic allergen‑specific immunotherapy
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34.2 ± 9.5  years, and 19 subjects (59.4%) were female. 
The mean symptom duration of AR was 14.5 ± 9.5 years. 
Subjects in the active group were younger than those in 
the control group (32.4 ± 11.1  years vs. 36.9 ± 5.9  years, 
P = 0.037). By contrast, gender and symptom duration 
did not differ significantly between the two groups. The 
most common allergic comorbidity was asthma (59.4%), 
followed by urticaria (21.9%), food allergy (18.8%), drug 
allergy (15.6%), and atopic dermatitis (12.5%). Twenty-
one subjects (65.6%) had a family history of allergy. The 
frequencies of comorbid allergic diseases and a fam-
ily history of allergy did not differ significantly between 
the two groups. The target allergens were D. farinae, D. 
pteronyssinus, cat, and dog extracts for 22 (68.8%), 21 
(65.6%), 19 (59.4%), and 8 (25.0%) subjects, respectively; 
no significant differences in the frequencies of each target 
allergen were observed between the groups. Among the 
subjects followed-up at 4 months and 1 year, age, gender, 
symptom duration, allergic comorbidities, family history 
of allergy, and target allergens did not differ between the 
two groups.
Safety of ILAIT
On the day of the first intralymphatic injection, sub-
jects reported that intralymphatic injection-caused pain 
was mild but more intense than venous punctures (VAS 
score: 3.5 ± 2.0  mm vs. 2.8 ± 1.7  mm, P = 0.019; Fig.  3). 
Although intralymphatic injection seemed to be more 
painful than venous punctures, the difference in pain was 
not significant within each group (treatment-group VAS 
scores: 3.4 ± 2.1 mm vs. 2.8 ± 1.8 mm, P = 0.092; control 
VAS scores: 3.7 ± 1.9  mm vs. 2.9 ± 1.6  mm, P = 0.106). 
The extent of pain caused by intralymphatic injection and 
venous puncture did not differ significantly between the 
two groups.
Local and systemic adverse events are summarized in 
Table 2. Pain was the most frequent local adverse event 
(12.8%), followed by itchiness (8.5%), paresthesia (6.4%), 
wheal (1.1%), and sensation of heat (1.1%) at the site of 
intralymphatic injection. The most frequent systemic 
adverse events were dyspnea (5.3%) and wheezing (5.3%), 
followed by chest discomfort (4.3%), headache (3.2%), 
chills (3.2%), palpitation (2.1%), urticaria (2.1%), itchy 
eyes (2.1%), itchy palms (2.1%), abdominal discomfort 
(1.1%), fever (1.1%), rhinorrhea (1.1%), postnasal drip 
(1.1%), and sneezing (1.1%). No significant differences in 
systemic and local adverse events were observed between 
the two groups. According to Müller’s classification, four 
(one in the active group and three in the control group) 
and one (in the active group) subjects developed sys-
temic hypersensitivity reactions of grade 1 and grade 3, 
respectively. The subject that developed a severe hyper-
sensitivity reaction (grade 3) after the first intralymphatic 
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Fig. 3 Pain of intralymphatic injection. On the day of the first intralymphatic injection, blood sampling was also performed. subjects were asked to 
compare the pain of intralymphatic injection to that of a venous puncture. Box plots show median (line), 24th and 75 percentiles (box), and ranges 
(whiskers). *P < 0.05
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accompanied by dyspnea, chest and abdominal discom-
fort, palpitation, chills, and itchy palms. Although the 
allergen was further diluted 1,000-fold for the second 
intralymphatic injection, the subject experienced mild 
paresthesia at the injection site. The allergen’s concentra-
tion was increased tenfold for the third intralymphatic 
injection, and the subject complained of pain and par-
esthesia at the injection site accompanied by fever and 
chills. For other subjects in the active group who had no 
reactions or a mild hypersensitivity reaction (grade 0–1), 
allergen concentrations were increased three-fold for the 
second intralymphatic injection and tenfold for the third 
intralymphatic injection.
Symptom relief and rescue medication use
The overall AR symptoms scored on a VAS did not 
change significantly in the treatment or control 
groups at 4  months or 1  year after treatment, and 
the scores did not differ between active and con-
trol groups at 4  months (VAS score: 37.9 ± 27.6  mm 
vs. 38.4 ± 21.7  mm, P = 0.805) and 1  year (VAS score: 
47.7 ± 26.5  mm vs. 33.3 ± 22.9  mm, P = 0.186) after 
treatment (Fig. 4A). In the active group, the total mean 
scores of SNOT-20 and RQLQ and the mean domain 
score of the emotional function domain in RQLQ did 
not change significantly at 4  months or 1  year after 
treatment; however, these scores were significantly 
reduced at 4  months and/or 1  year after treatment in 
the control group (Fig. 4B—C and Additional file 1:Fig. 
S1A). The mean total scores of SNOT-20 and RQLQ 
and the mean domain score of the emotional func-
tion domain in RQLQ did not differ between active 
and control groups at 4 months (SNOT-20: 1.12 ± 1.12 
vs. 1.12 ± 1.01, P = 0.773; RQLQ: 1.10 ± 0.88 vs. 
1.16 ± 0.79, P = 0.805; the emotional function domain 
in RQLQ: 1.03 ± 0.82 vs. 1.02 ± 1.04, P = 0.742) and 
1 year (SNOT-20: 1.83 ± 1.63 vs. 1.43 ± 1.20, P = 0.695; 
RQLQ: 1.35 ± 0.89 vs. 1.01 ± 0.83, P = 0.262; the emo-
tional function domain in RQLQ: 1.04 ± 0.89 vs. 
0.92 ± 1.14, P = 0.471) after treatment. Mean domain 
Table 2 Adverse events associated with the intralymphatic injections in the cohort for testing procedural safety (n = 32)
Data are shown in frequencies (%). *Hypersensitivity reactions were graded according to Müller’s classification
All subjects (94 injections) Active group (55 injections) Control group (39 injections) P-value
Local reactions
 Pain 12 (12.8) 9 (16.4) 3 (7.7) 0.178
 Itch 8 (8.5) 6 (10.9) 2 (5.1) 0.275
 Paresthesia 6 (6.4) 4 (7.3) 2 (5.1) 0.513
 Wheal 1 (1.1) 0 (0.0) 1 (1.8) 0.415
 Heat sensation 1 (1.1) 1 (1.8) 0 (0.0) 0.585
Systemic reaction
 Dyspnea 5 (5.3) 3 (5.5) 2 (5.1) 0.660
 Wheezing 5 (5.3) 3 (5.6) 2 (5.1) 0.660
 Chest discomfort 4 (4.3) 4 (7.3) 0 (0.0) 0.112
 Headache 3 (3.2) 2 (3.6) 1 (2.6) 0.628
 Chills 3 (3.2) 2 (3.6) 1 (2.6) 0.628
 Palpitation 2 (2.1) 2 (3.6) 0 (0.0) 0.340
 Urticaria 2 (2.1) 1 (1.8) 1 (2.6) 0.660
 Itchy eyes 2 (2.1) 0 (0.0) 2 (5.1) 0.170
 Itchy palms 1 (1.1) 1 (1.8) 0 (0.0) 0.585
 Abdominal discomfort 1 (1.1) 1 (1.8) 0 (0.0) 0.585
 Fever 1 (1.1) 1 (1.8) 0 (0.0) 0.585
 Rhinorrhea 1 (1.1) 0 (0.0) 1 (2.6) 0.415
 Postnasal drip 1 (1.1) 0 (0.0) 1 (2.6) 0.415
 Sneezing 1 (1.1) 0 (0.0) 1 (2.6) 0.415
Hypersensitivity reactions* 0.273
 Grade 0 (none) 88 (94.6) 52 (94.5) 36 (94.7)
 Grade 1 (mild) 4 (4.3) 1 (1.8) 3 (7.7)
 Grade 2 (moderate) 0 (0.0) 0 (0.0) 0 (0.0)
 Grade 3 (severe) 1 (1.1) 1 (1.8) 0 (0.0)
 Grade 4 (anaphylactic) 0 (0.0) 0 (0.0) 0 (0.0)
Page 8 of 13Park et al. Respir Res          (2021) 22:170 
scores of practical problem, sleep, and non-nose/eye 
symptoms domain in RQLQ decreased significantly at 
4 months and/or 1 year after treatment in both groups 
(Additional file 1:Fig. S1B–D). They were not different 
between active and control groups at 4  months (the 
practical problem domain: 0.90 ± 0.90 vs. 1.04 ± 0.94, 
P = 0.711; the sleep domain: 0.94 ± 1.10 vs. 0.90 ± 0.69, 
P = 0.711; the non-nose/eye symptoms domain: 
1.04 ± 1.18 vs. 1.14 ± 1.00, P = 0.621) and 1  year (the 
practical problem domain: 1.29 ± 1.14 vs. 0.97 ± 0.91, 
P = 0.601; the sleep domain: 1.51 ± 1.23 vs. 0.93 ± 0.88, 
P = 0.262; the non-nose/eye symptoms domain: 
1.40 ± 1.19 vs. 1.04 ± 0.87, P = 0.556) after treatment. 
Meanwhile, mean domain scores of nasal and ocular 
symptoms domain in RQLQ did not change during 
the study period in either group, nor did they differ 
between active and control groups at 4  months (the 
nasal symptoms domain: 1.62 ± 0.90 vs. 1.50 ± 0.77, 
P = 0.773; the ocular symptoms domain: 1.19 ± 0.90 
vs. 1.21 ± 1.12, P = 0.837) and 1  year (the nasal symp-
toms domain: 1.79 ± 0.86 vs. 1.33 ± 0.98, P = 0.324; the 
ocular symptoms domain: 1.02 ± 0.92 vs. 0.86 ± 0.87, 
P = 0.601) after treatment (Additional file  1: Fig. S1E, 
F).
Diaries of daily symptom and medication were 
returned by 27 subjects (16 in the active group and 11 
in the control group); however, only 21 (13 in the active 
group and eight in the control group) and 10 (six in the 
active group and four in the control group) completed 
the reports for the 4-month and 1-year follow-up, 
respectively. According to these reports, the dSS did 
not change significantly in either group (Fig.  5A). The 
dSS did not differ between active and control groups 
at 4  months (mean daily score: 3.8 ± 3.4 vs. 2.4 ± 1.9, 
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Fig. 4 Symptom relief and quality of life. A Subject‑reported overall symptom of allergic rhinitis. Study subjects were asked to score their overall 
symptom of allergic rhinitis on a VAS. B Total mean score of SNOT‑20. C Total mean score of RQLQ. *P < 0.05. VAS visual analog scale, SNOT-20 
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Fig. 5 Daily symptom and medication use. A daily symptom score (dSS). B daily medication score (dMS). C daily symptom medication score 
(dSMS). *P < 0.05
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3.0 ± 2.8, P = 0.610) after treatment. Meanwhile, the 
dMS decreased significantly at 4  months after treat-
ment in the active group but not in the control group 
(Fig. 5B). However, the dMS was not different between 
active and control groups at 4  months (mean daily 
score: 2.7 ± 3.1 vs. 6.6 ± 5.7, P = 0.076) and 1  year 
(mean daily score: 3.4 ± 3.6 vs. 0.3 ± 0.6, P = 0.067) after 
treatment, which may be due to the small number of 
subjects who completed the diary. In both groups, the 
dSMS decreased significantly at 4  months and/or at 
1 year after treatment (Fig. 5C). The dSMS was not dif-
ferent between active and control groups at 4  months 
(mean daily score: 6.7 ± 4.7 vs. 7.7 ± 7.4, P = 0.970) 
and 1  year (mean daily score: 11.0 ± 5.1 vs. 6.9 ± 7.8, 
P = 0.181) after treatment.
Skin reactivity
In the active group, skin reactivity to serial dilutions of 
HDM allergen decreased at 4  months after treatment 
(P < 0.05 for the  103-fold dilution), then this reduction in 
skin reactivity diminished at 1 year after treatment, how-
ever the reduction in skin reactivity to  103- and tenfold 
dilutions of HDM allergen remained significant (Addi-
tional file  2: Fig. S2A). On the contrary, in control sub-
jects, skin reactivity after exposure to serial dilutions of 
HDM allergen increased at 4  months after treatment 
(P < 0.05 for the  107-,  106-,  105-,  104-,  103-, and  102-fold 
dilutions compared with baseline).
Skin reactivity to serial dilutions of cat allergens 
decreased at 4  months after treatment in the active 
group, and it was significantly lower than that in the 
control group (P < 0.05 for the  107-,  106-,  105-,  104-, and 
 103-fold dilutions compared with the control group), 
then this reduction in skin reactivity diminished at 1 year 
after treatment (Additional file  2: Fig. S2B). In control 
subjects, skin reactivity to serial dilutions of cat allergens 
generally increased at 4 months, then decreased at 1 year 
after treatment, but the changes were not significant.
In the active group, skin reactivity after exposure to 
serial dilutions of dog allergens decreased at 4  months 
after treatment and increased at 1  year after treatment 
(Additional file  2: Fig. S2C). In control subjects, skin 
reactivity to serially diluted dog allergens increased at 
4  months and 1  year after treatment; nevertheless, skin 
reactivity changes were not statistically significant in 
either group.
The IDT results revealed that skin reactivity to serially 
diluted HDM, cat, and dog allergens did not change sig-
nificantly during the study period and that no differences 
existed between the two groups (Additional file  3: Fig. 
S3).
Nasal reactivity
Among the 12 subjects who underwent the NAPT with 
the D. farinae allergen, nasal and ocular symptoms 
decreased at 4 months and 1 year after treatment in both 
groups; however, these changes were not statistically 
significant (Fig.  6A). Similarly, no significant alterations 
in nasal cavity volume were observed during the study 
period (Fig.  6B). Nasal or ocular symptoms and nasal 
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Symptom Nasal cavity volumeA B
Fig. 6 Nasal reactivity in NAPT with serially diluted Dermatophagoides farinae allergen. A The AUC of the sum of 5 VAS scores (total range 0–500). B 
The AUC of the mean value of volume  (cm3) in the anterior nasal segment (Volume 2–6 cm). VAS, visual analogue scale; AUC, area under curve
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between two groups before treatment and at 4  months 
and 1 year after treatment.
Basophil reactivity
Among the 15 subjects who provided blood samples, the 
percentages of activated  CD63+ basophils after in  vitro 
stimulation with D. farinae, D. pteronyssinus, and cat 
allergens, decreased at 4  months and 1  year after treat-
ment in the active group, although not significantly. No 
changes in the percentages of activated  CD63+ basophils 
were observed in control subjects (Additional file 4: Fig. 
S4A–C). We could not evaluate the changes in the per-
centage of activated  CD63+ basophils after in vitro stim-
ulation with dog allergens due to the small number of 
subjects (two in the active group and one in the control 
group; Additional file 4: Fig. S4D.
Discussion
In 2008, Senti et  al. first described ILAIT as a promis-
ing AIT that can alleviate nasal reactivity to pollen aller-
gens as fast as within 4  months after treatment, which 
is significantly faster than with SCIT. In the open-label 
randomized study by Senti et al., ILAIT alleviated nasal 
reactivity for up to 3  years in patients with pollen-
induced AR [1]. Moreover, ILAIT has been shown to 
reduce allergic symptoms, serum pollen-specific IgE lev-
els, and skin reactivity to the allergen for up to 3  years 
after treatment. Notably, compared with patients treated 
with SCIT, fewer ILAIT-treated patients required res-
cue medications. Subsequent open-label pilot studies 
confirmed that ILAIT alleviated nasal or ocular symp-
toms, improved the QOL, decreased nasal reactivity as 
observed in the NAPT and allergen-specific IgE serum 
levels, as well as increased allergen-specific IgG4 serum 
levels and the number of plasmablasts producing grass 
pollen-specific immunoglobulins other than IgE [5, 7]. 
However, nasal reactivity, nasal and ocular symptoms, 
and QOL are largely self-reported and subject to con-
founding effects, thus introducing bias and uncertainty 
regarding the therapeutic efficacy of AIT. Therefore, dou-
ble-blind placebo-controlled (DBPC) trials are required 
to elucidate the clinical efficacy of AIT objectively [28, 
29].
Thus far, six DBPC trials have evaluated the therapeutic 
efficacy and adverse effects of ILAIT in patients with pol-
len-induced AR [2–4, 6, 8–11]. In a DBPC trial with 15 
subjects, Hylander et al. reported that ILAIT with birch 
or grass pollen improved seasonal allergic symptoms, 
decreased rescue medication use, and increased the 
activation levels of  CD4+ T cells in the peripheral blood 
[2]. ILAIT also alleviated nasal reactivity to allergens 
and reduced the levels of the proinflammatory cytokine 
interleukin (IL)-8 in nasal fluids, although these effects 
were not statistically significant.
In a follow-up study with 20 additional subjects, they 
found that ILAIT modestly alleviated seasonal allergic 
symptoms. Moreover, ILAIT decreased nasal reactivity 
and IgG4 affinity to allergens in individuals who exhib-
ited symptom improvement, although nasal reactivity 
did not differ significantly between treated and control 
subjects [3]. In a subsequent clinical trial with 60 patients 
sensitized to both birch and grass pollen allergens, ILAIT 
significantly improved the QOL during birch pollen but 
not grass pollen season [4]. They also found that ILAIT 
decreased rescue medication use during birch and grass 
pollen seasons, as well as reduced nasal reactivity to grass 
pollen and skin reactivity to birch and grass pollen; how-
ever, the overall improvement in symptoms did not differ 
significantly between the treatment and control groups. 
In a recent study, allergic patients received a booster dose 
at 1  year after three pre-seasonal intralymphatic injec-
tions of birch or timothy pollen; the booster dose further 
decreased the symptom and medication scores during 
the second pollen season compared with the first pollen 
season [8]. However, the study was unblinded after the 
end of the first pollen season, and no symptom or medi-
cation scores were recorded in the control group during 
the second pollen season.
Witten et al. assessed the usefulness of ILAIT for treat-
ing timothy grass (Phleum pretense) allergy and found 
that seasonal symptoms, QOL, skin or nasal reactivity to 
allergens, intracellular cytokine levels, regulatory T-cell 
marker expression, and histamine release levels did not 
differ significantly between the treatment and control 
groups [11]. By contrast, Patterson et  al. reported that 
in subjects with a timothy grass allergy, ILAIT reduced 
the total combined score of symptoms and medica-
tions; however, Patterson et  al. used different allergen 
concentrations and injection intervals from those used 
by Witten et  al. [6]. Two recent DBPC trials reported 
that in individuals with Japanese cedar and mountain 
cedar allergies, ILAIT alleviated allergic symptoms and 
reduced rescue medication use [9, 10]; nevertheless, fur-
ther investigations are required to confirm these thera-
peutic outcomes. The usefulness of ILAIT for treating 
pollen-induced AR remains unclear [30, 31].
The clinical efficacy of ILAIT against non-pollen-
induced allergies was first assessed by Senti et  al. [12]. 
In a DBPC study, Senti et  al. showed that ILAIT with 
recombinant cat allergens reduced nasal and skin reac-
tivity, as well as increased cat-specific IgG4 serum levels 
and IL-10 production levels. In a recent open-label pilot 
study in China, cervical ILAIT improved nasal and ocular 
symptoms and QOL, as well as reduced rescue medica-
tion use in individuals with a HDM allergy [16]. However, 
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the study did not include a control group, and the safety 
of cervical ILAIT was not comprehensively investigated.
Unlike the aforementioned studies, which used alu-
minum hydroxide-absorbed allergen extracts, in our 
previous open-label pilot studies, we evaluated the clini-
cal efficacy and safety of ILAIT with aqueous allergen 
extracts of D. farinae, D. pteronyssinus, cat, dog, or mix-
tures thereof [14, 15]. Although ILAIT improved allergic 
symptoms and the QOL, in some study subjects, ILAIT 
provoked severe local and systemic hypersensitivity 
reactions, especially in individuals treated with aqueous 
HDM allergens [14, 15]. Hence, we substituted aque-
ous allergen extracts with tyrosine-adsorbed allergen 
extracts, which are considered safer [32]. However, one 
patient experienced a severe hypersensitivity reaction 
(grade 3) after ILAIT using tyrosine-adsorbed allergen 
extracts. With regard to local reactions, intralymphatic 
injection was proven to be more painful than venous 
puncture in this study. Previous studies also reported 
moderate-to-severe hypersensitivity reactions after 
ILAIT [5, 7]. Thus, future studies are required to improve 
the safety of ILAIT. Additionally, a novel AIT such as 
epicutaneous immunotherapy using microneedles or 
adhesive-tape stripping can be an alternative modality 
that can minimize the risks of local and systemic adverse 
reactions [33, 34].
The findings of this study suggest that ILAIT using 
tyrosine-adsorbed allergen extracts does not significantly 
alleviate AR induced by HDM, cat, or dog allergens. The 
relatively small number of subjects might have contrib-
uted to the insignificant efficacy of ILAIT for treating 
AR, although previous DBPC trials reported conclusive 
findings with a smaller number of subjects than that used 
in our study [2, 6, 12]. Alternatively, the ILAIT schedule 
(three intralymphatic injections at 4-week intervals) and 
doses used might have been insufficient to exert a thera-
peutic effect, given that most outcomes assessed did not 
differ significantly between the two groups. Additionally, 
only short-term reductions in rescue medication use, as 
well as partial improvements in QOL and skin reactivity 
response were observed after treatment.
Conclusion
ILAIT with tyrosine-adsorbed allergen extracts had no 
definite therapeutic effect on AR induced by HDM, cat, 
or dog allergens, although it may reduce rescue medi-
cation use, and partially improve QOL and skin reac-
tivity responses. Additionally, ILAIT may provoke a 
severe hypersensitivity reaction; thus, future studies are 
required to elucidate the clinical efficacy and safety of 
ILAIT with various allergen extracts.
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